You are here

  • Home
  • Archive
  • Volume 77, Issue 11
  • Platelet activation, as measured by plasma soluble glycoprotein VI, is not associated with disease activity or ischaemic events in giant cell arteritis

Article Text

Article menu
Download PDFPDF
Letter
Platelet activation, as measured by plasma soluble glycoprotein VI, is not associated with disease activity or ischaemic events in giant cell arteritis
  1. Richard Conway1,2,
  2. Anne Madigan1,
  3. Niamh Redmond3,
  4. Laura Helbert1,
  5. Eamonn S Molloy4,
  6. Eimear Dunne5,
  7. Dermot Kenny5,
  8. Geraldine McCarthy1
  1. 1 Department of Rheumatology, Mater Misericordiae University Hospital, Dublin Academic Medical Centre, Dublin, Ireland
  2. 2 CARD Newman Research Fellow, University College Dublin, Dublin, Ireland
  3. 3 Clinical Research Centre, Mater Misericordiae University Hospital, Dublin Academic Medical Centre, Dublin, Ireland
  4. 4 Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent’s University Hospital, Dublin, Ireland
  5. 5 Cardiovascular Biology and Clinical Research Centre, Royal College of Surgeons in Ireland, Dublin, Ireland
  1. Correspondence to Dr Richard Conway, Department of Rheumatology, Mater Misericordiae University Hospital, Dublin Academic Medical Centre, Dublin D07 R2WY, Ireland; drrichardconway{at}gmail.com

https://doi.org/10.1136/annrheumdis-2018-213487

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Giant cell arteritis (GCA) is associated with cranial ischaemic complications (CIC) including vision loss and stroke.1 British Society of Rheumatology and European League against Rheumatism guidelines recommend platelet inhibition with aspirin for most patients with GCA; on the basis of two retrospective studies showing a reduction in CICs, these results were not replicated in two other retrospective studies.2 3 There are no data from prospective or randomised controlled trials to support aspirin use in GCA.4 The glycoprotein VI (GPVI) receptor is found exclusively on platelets and megakaryocytes.5 GPVI is proteolytically cleaved following platelet activation and is detectable in plasma as soluble GPVI (sGPVI).6 Elevated plasma sGPVI signifies platelet activation and an increased risk of cardiovascular events.7 We have recently demonstrated enhanced platelet reactivity as measured by sGPVI in gout and rheumatoid arthritis, …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors RC, DK and GMC conceived the study. RC performed the data analysis. All authors critically appraised the manuscript and approved the final version.

    • Funding This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Mater Misericordiae University Hospital Ethics Committee.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement Data used in this study are held in the Department of Rheumatology, Mater Misericordiae University Hospital, Dublin, Ireland, under the custody of GMC and can be made available on request.

    • Presented at The results from this study were presented at the American College of Rheumatology Annual Meeting 2016 and have been published in abstract form: Conway R et al.10